Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 41: 908-913, 1995;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Joven, J.
Right arrow Articles by Villabona, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Joven, J.
Right arrow Articles by Villabona, C.

Clinical Chemistry, Vol 41, 908-913, Copyright © 1995 by American Association for Clinical Chemistry

Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria

J Joven, JM Simo, E Vilella, J Camps, E Espinel and C Villabona
Hospital Universitari de Sant Joan, Reus, Spain.

Although lipoprotein abnormalities of the nephrotic syndrome are assumed to be related to the presence of proteinuria, this topic has not been investigated extensively. We measured lipoproteins from 19 nonuremic patients during and after remission of the nephrotic syndrome in an effort to determine the extent of their putative atherogenicity. As expected, disturbances involved primarily the apoprotein B- containing lipoproteins. No patient showed serum lipoprotein(a) [Lp(a)] < 300 mg/L during the acute phase. Lp(a) concentrations correlated significantly with those of apoprotein B, and both values decreased dramatically with the remission of the nephrotic syndrome. Surprisingly, despite the resolution of proteinuria, concentrations of intermediate-density lipoproteins and Lp(a) remained above normal in hypertriglyceridemic patients, suggesting a residual effect of nephrosis in the overall lipoprotein transport. Accumulation of atherogenic remnants should be considered a characteristic of the hyperlipidemia of the nephrotic syndrome, and aggressive treatment to reduce proteinuria is mandatory.


The following articles in journals at HighWire Press have cited this article:


Home page
 J. Am. Soc. Nephrol.Home page
G. A. Kaysen and J. P. Eiserich
The Role of Oxidative Stress-Altered Lipoprotein Structure and Function and Microinflammation on Cardiovascular Risk in Patients with Minor Renal Dysfunction
J. Am. Soc. Nephrol., March 1, 2004; 15(3): 538 - 548.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. M a Simo, I. Castellano, N. Ferre, J. Joven, and J. Camps
Evaluation of a homogeneous assay for high-density lipoprotein cholesterol: limitations in patients with cardiovascular, renal, and hepatic disorders
Clin. Chem., June 1, 1998; 44(6): 1233 - 1241.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. Braschi, D. Masson, G. Rostoker, E. Florentin, A. Athias, C. Martin, B. Jacotot, P. Gambert, C. Lallemant, and L. Lagrost
Role of Lipoprotein-Bound NEFAs in Enhancing the Specific Activity of Plasma CETP in the Nephrotic Syndrome
Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2559 - 2567.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
J. Joven, X. Cliville, J. Camps, E. Espinel, J. Simo, E. Vilella, and A. Oliver
Plasma protein abnormalities in nephrotic syndrome: effect on plasma colloid osmotic pressure and viscosity
Clin. Chem., July 1, 1997; 43(7): 1223 - 1231.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Association for Clinical Chemistry.